Literature DB >> 22552929

Preformulation study of NSC-726796.

Duoli Guo1, James P Cain, Sean O'Connell, Erin R Gardner, Steven Pisle, William D Figg, S Esmail Tabibi, Samuel H Yalkowsky.   

Abstract

A stability-indicating high-performance liquid chromatography method to quantify 2-(2,4-difluorophenyl)-4,5,6,7-tetrafluoroisoindoline-1,3-dione (NSC-726796) and its three main degradation products was developed. This method was used to investigate its degradation kinetics and mechanism. The reaction follows first-order kinetics and appears to be base catalyzed with the maximum stability at pH 1. The products were identified as 2-(2,4-difluorophenylcarbamoyl)-3,4,5,6-tetrafluorobenzoic acid (NSC-749820), 2,4-difluoroaniline, and tetrafluorophthalic acid. The parent drug, NSC-726796, was also found to react with methanol and ethanol. NSC-726796 demonstrates antiangiogenic activity, however, when its degradant NSC749820 does not show antiangiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552929      PMCID: PMC3364376          DOI: 10.1208/s12249-012-9784-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  7 in total

1.  Selective leukemic-cell killing by a novel functional class of thalidomide analogs.

Authors:  Yun Ge; Idalia Montano; Gabriella Rustici; Wendy J Freebern; Cynthia M Haggerty; Wenwu Cui; Damaris Ponciano-Jackson; G V R Chandramouli; Erin R Gardner; William D Figg; Mones Abu-Asab; Maria Tsokos; Sharon H Jackson; Kevin Gardner
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

2.  Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.

Authors:  S Kumar; N Raje; T Hideshima; K Ishitsuka; A Roccaro; N Shiraishi; M Hamasaki; H Yasui; N C Munshi; P Richardson; W D Figg; K C Anderson
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

3.  Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.

Authors:  Noel A Warfel; Erin R Lepper; Chunyu Zhang; William D Figg; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

4.  Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.

Authors:  Erin R Lepper; Sylvia S W Ng; Michael Gütschow; Michael Weiss; Sunna Hauschildt; Thomas K Hecker; Frederick A Luzzio; Kurt Eger; William D Figg
Journal:  J Med Chem       Date:  2004-04-22       Impact factor: 7.446

5.  Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Authors:  Sylvia S W Ng; Michael Gütschow; Michael Weiss; Sunna Hauschildt; Uwe Teubert; Thomas K Hecker; Frederick A Luzzio; Erwin A Kruger; Kurt Eger; William D Figg
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

6.  Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.

Authors:  Sylvia S W Ng; Gordon R MacPherson; Michael Gütschow; Kurt Eger; William D Figg
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

7.  Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.

Authors:  Yun Ge; Jung S Byun; Paola De Luca; Geraldine Gueron; Idalia M Yabe; Sara G Sadiq-Ali; William D Figg; Jesse Quintero; Cynthia M Haggerty; Quentin Q Li; Adriana De Siervi; Kevin Gardner
Journal:  Mol Pharmacol       Date:  2008-06-12       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.